Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Montse Sánchez-Céspedes"'
Autor:
Lucía Notario, Marc Cucurull, Gabriela Cerdà, Carolina Sanz, Enric Carcereny, Ana Muñoz-Mármol, Ainhoa Hernández, Marta Domènech, Teresa Morán, Montse Sánchez-Céspedes, Marta Costa, Jose-Luis Mate, Anna Esteve, Maria Saigí
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Approximately 20% of lung adenocarcinomas harbor activating mutations at KRAS, an oncogene with the ability to alter the tumor immune microenvironment. In this retrospective study, we examined 103 patients with KRAS-mutant lung adenocarcinoma who wer
Externí odkaz:
https://doaj.org/article/6460f628e9154bd29ea1ff2e9b47c256
Autor:
Esther Conde, Bárbara Angulo, Pilar Redondo, Oscar Toldos, Elena García-García, Ana Suárez-Gauthier, Belén Rubio-Viqueira, Carmen Marrón, Ricardo García-Luján, Montse Sánchez-Céspedes, Angel López-Encuentra, Luis Paz-Ares, Fernando López-Ríos
Publikováno v:
PLoS ONE, Vol 5, Iss 8, p e12209 (2010)
INTRODUCTION: While some targeted agents should not be used in squamous cell carcinomas (SCCs), other agents might preferably target SCCs. In a previous microarray study, one of the top differentially expressed genes between adenocarcinomas (ACs) and
Externí odkaz:
https://doaj.org/article/bcc075bd7c134c009a82c71094867c90
Autor:
Montse Sánchez-Céspedes
Publikováno v:
Clinical and Translational Oncology. 11:263-269
Lung cancer is the leading cause of death due to cancer in most western countries and, as tobacco consumption is not significantly decreasing worldwide, will remain so in the coming decades. Thus, in addition to preventing uptake and encouraging cess
Autor:
Octavio A. Romero, Andrea Vilarrubi, Juan J. Alburquerque-Bejar, Antonio Gomez, Alvaro Andrades, Deborah Trastulli, Eva Pros, Fernando Setien, Sara Verdura, Lourdes Farré, Juan F. Martín-Tejera, Paula Llabata, Ana Oaknin, Maria Saigi, Josep M. Piulats, Xavier Matias-Guiu, Pedro P. Medina, August Vidal, Alberto Villanueva, Montse Sanchez-Cespedes
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
SMARCA4 is commonly inactivated in lung and ovarian cancers. Here the authors show that SMARCA4-deficient tumours have significantly reduced levels of the histone demethylases KDM6s and a strong dependency on these demethylases for tumour growth, so
Externí odkaz:
https://doaj.org/article/c8c005713fd44b6bbb0151fbe7d89bec
Autor:
Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, Susana Cedrés, Alex Martinez‐Marti, Nuria Pardo, Nadia Saoudi‐Gonzalez, Debora Martinez, Jose Jimenez, Irene Sansano, Francesco M. Mancuso, Paolo Nuciforo, Luis M. Montuenga, Montse Sánchez‐Cespedes, Aleix Prat, Ana Vivancos, Enriqueta Felip, Ramon Amat
Publikováno v:
Molecular Oncology, Vol 15, Iss 4, Pp 887-900 (2021)
Immunotherapy has transformed advanced non‐small cell lung cancer (NSCLC) treatment strategies and has led to unprecedented long‐lasting responses in some patients. However, the molecular determinants driving these long‐term responses remain el
Externí odkaz:
https://doaj.org/article/5d71f89668ed4454856fe4896f4856ea
Autor:
Marc Cucurull, Lucia Notario, Montse Sanchez-Cespedes, Cinta Hierro, Anna Estival, Enric Carcereny, Maria Saigí
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor immune microenvironment. While KRAS was considered “undruggable” for decades, spec
Externí odkaz:
https://doaj.org/article/ffbe2d7461754e19b5b912b54bef0fbb